scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1004035368 |
P356 | DOI | 10.1038/SJ.ONC.1209179 |
P698 | PubMed publication ID | 16331274 |
P50 | author | David Bernard | Q44039079 |
Tapio Visakorpi | Q49957442 | ||
Jesus Gil | Q55472013 | ||
Didier Monté | Q56872770 | ||
P2093 | author name string | Y de Launoit | |
S Rizzo | |||
P Dumont | |||
D Hudson | |||
F Fuks | |||
B Quatannens | |||
P2860 | cites work | The Hallmarks of Cancer | Q221226 |
Identification of c-MYC as a target of the APC pathway | Q24310637 | ||
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex | Q24324026 | ||
A census of human cancer genes | Q24647081 | ||
MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex | Q28143627 | ||
DNA methyltransferases get connected to chromatin | Q28202206 | ||
Molecular determinants of resistance to antiandrogen therapy | Q28236889 | ||
Myc activates telomerase | Q28505489 | ||
Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1 | Q28575665 | ||
The development of androgen-independent prostate cancer | Q29615650 | ||
DNA hypermethylation in tumorigenesis: epigenetics joins genetics | Q33870798 | ||
A history of prostate cancer treatment | Q34013878 | ||
Molecular genetics of prostate cancer. | Q34052664 | ||
Emerging connections between DNA methylation and histone acetylation. | Q34298959 | ||
Polycomb complexes and silencing mechanisms. | Q34320981 | ||
Histone deacetylase as a new target for cancer chemotherapy. | Q34392069 | ||
DNA methyltransferase inhibitors-state of the art. | Q34990742 | ||
Tumor p53 status and response to topoisomerase II inhibitors | Q35091149 | ||
The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. | Q35137797 | ||
Strategies for reversing drug resistance | Q35567287 | ||
The molecular genetics of prostate cancer. | Q35579585 | ||
Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence | Q35645358 | ||
DNA methylation in prostate cancer | Q35885689 | ||
Transcriptional regulation of prostate kallikrein-like genes by androgen | Q38329109 | ||
Myc confers androgen-independent prostate cancer cell growth | Q40271517 | ||
Preferential response of cancer cells to zebularine. | Q40523300 | ||
The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation | Q40690782 | ||
Lack of RB protein correlates with increased sensitivity to UV-radiation-induced apoptosis in human breast cancer cells | Q40850195 | ||
p53 oncogene mutations in three human prostate cancer cell lines | Q41586000 | ||
DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. | Q46784718 | ||
Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells | Q47875189 | ||
Functional analyses of MeCP2 mutations associated with Rett syndrome using transient expression systems | Q48693103 | ||
Dysregulated expression of beta-catenin marks early neoplastic change in Apc mutant mice, but not all lesions arising in Msh2 deficient mice. | Q53415845 | ||
Deficiency of Mbd2 suppresses intestinal tumorigenesis | Q57247922 | ||
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases | Q57693579 | ||
Prostatic carcinoma: histological and immunohistological factors affecting prognosis | Q68578366 | ||
The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker" | Q69794650 | ||
Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases | Q70169490 | ||
Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment | Q73459527 | ||
Prostate cancer | Q73703143 | ||
DNA methylation and cancer | Q74559063 | ||
Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy | Q77651935 | ||
Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells | Q77932887 | ||
Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy | Q79920255 | ||
Molecular mechanisms of prostate cancer | Q80101555 | ||
P433 | issue | 9 | |
P921 | main subject | cell growth | Q189159 |
prostate cancer | Q181257 | ||
P304 | page(s) | 1358-1366 | |
P577 | publication date | 2006-03-01 | |
P1433 | published in | Oncogene | Q1568657 |
P1476 | title | The methyl-CpG-binding protein MECP2 is required for prostate cancer cell growth | |
P478 | volume | 25 |
Q36394208 | A Tox21 Approach to Altered Epigenetic Landscapes: Assessing Epigenetic Toxicity Pathways Leading to Altered Gene Expression and Oncogenic Transformation In Vitro |
Q92723391 | A central role for MeCP2 in the epigenetic repression of miR-200c during epithelial-to-mesenchymal transition of glioma |
Q34027447 | CFIm25 links alternative polyadenylation to glioblastoma tumour suppression. |
Q93065274 | DNA Methylation Readers and Cancer: Mechanistic and Therapeutic Applications |
Q34998222 | DNA binding restricts the intrinsic conformational flexibility of methyl CpG binding protein 2 (MeCP2). |
Q31097619 | Functional Profiling of Human MeCP2 by Automated Data Comparison Analysis and Computerized Expression Pathway Modeling |
Q37334003 | Functional connection between deimination and deacetylation of histones |
Q39709698 | Insights into the role of DNA methylation in disease through the use of mouse models |
Q34333224 | Knock-down of methyl CpG-binding protein 2 (MeCP2) causes alterations in cell proliferation and nuclear lamins expression in mammalian cells |
Q38646785 | MECP2 expression in gastric cancer and its correlation with clinical pathological parameters |
Q37376407 | MECP2 promotes the growth of gastric cancer cells by suppressing miR-338-mediated antiproliferative effect |
Q36803783 | Mechanisms of disease: methyl-binding domain proteins as potential therapeutic targets in cancer |
Q24324098 | Methyl-CpG-binding protein 2 is phosphorylated by homeodomain-interacting protein kinase 2 and contributes to apoptosis |
Q37783909 | MicroRNA dysregulation in gastric cancer: a new player enters the game |
Q35040740 | MicroRNA-4723 inhibits prostate cancer growth through inactivation of the Abelson family of nonreceptor protein tyrosine kinases |
Q42952032 | Multiple modes of interaction between the methylated DNA binding protein MeCP2 and chromatin. |
Q55082285 | Peptide SA12 inhibits proliferation of breast cancer cell lines MCF-7 and MDA-MB-231 through G0/G1 phase cell cycle arrest. |
Q38917420 | Preliminary screening of differentially expressed genes involved in methyl-CpG-binding protein 2 gene-mediated proliferation in human osteosarcoma cells |
Q36740636 | Proteins that bind methylated DNA and human cancer: reading the wrong words |
Q38194967 | Rett syndrome and MeCP2. |
Q34359158 | Rett syndrome with colon cancer presented with sigmoid volvulus: Report of a case |
Q40088472 | Rett syndrome-causing mutations in human MeCP2 result in diverse structural changes that impact folding and DNA interactions. |
Q92221539 | Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials |
Q39406654 | The stress oncoprotein LEDGF/p75 interacts with the methyl CpG binding protein MeCP2 and influences its transcriptional activity |
Q33860692 | Unique physical properties and interactions of the domains of methylated DNA binding protein 2. |
Q40020081 | Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins |
Search more.